alfuzosin has been researched along with Sensitivity and Specificity in 7 studies
alfuzosin: structure given in first source
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The construction and characterization of potentiometric membrane electrodes are described for the quantification of alfuzosin, a drug used in a mono- and combined therapy of benign prostatic hyperplasia (BPH)." | 7.74 | Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum. ( Gupta, B; Gupta, VK; Singh, AK, 2007) |
| "The construction and characterization of potentiometric membrane electrodes are described for the quantification of alfuzosin, a drug used in a mono- and combined therapy of benign prostatic hyperplasia (BPH)." | 3.74 | Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum. ( Gupta, B; Gupta, VK; Singh, AK, 2007) |
| " The validated method was successfully employed for bioavailability study after oral administration of 10 mg of alfuzosin hydrochloride and 5mg of solifenacin succinate tablet formulations in eight healthy volunteers under fed condition." | 1.35 | Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective alpha1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma. ( Jangid, AG; Mistri, HN; Pudage, A; Rathod, DM; Shrivastav, PS, 2008) |
| "An isocratic reversed phase high-performance liquid chromatographic (HPLC) method with ultraviolet detection at 245 nm has been developed for the determination of alfuzosin hydrochloride in dosage formulation." | 1.35 | Quantitation of alfuzosin hydrochloride in pharmaceutical formulations by RP-HPLC. ( Ganesh, M; Gangully, S; Kamalakannan, K; Rathinavel, G; Sivakumar, T; Tivari, R; Uppatyay, S, 2009) |
| "Alfuzosin." | 1.33 | Validated HPLC and HPTLC stability-indicating methods for determination of alfuzosin hydrochloride in bulk powder and pharmaceutical formulations. ( Abdel-Aaty Shehata, M; El-Weshahy, SA; Salah Fayed, A; Yehia Hassan, N, 2006) |
| "To construct and validate a short-form benign prostatic hypertrophy (BPH) health-related quality-of-life (HRQL) questionnaire which is more practical in use and as informative as the 20-item visual analogue scale questionnaire (QOL20) previously validated in French." | 1.30 | Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice. ( Comet, D; Grange, JC; Lukacs, B; Thibault, P, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mistri, HN | 1 |
| Jangid, AG | 1 |
| Pudage, A | 1 |
| Rathod, DM | 1 |
| Shrivastav, PS | 1 |
| Ganesh, M | 1 |
| Uppatyay, S | 1 |
| Tivari, R | 1 |
| Kamalakannan, K | 1 |
| Rathinavel, G | 1 |
| Gangully, S | 1 |
| Sivakumar, T | 1 |
| Wiesner, JL | 1 |
| Sutherland, FC | 1 |
| van Essen, GH | 1 |
| Hundt, HK | 1 |
| Swart, KJ | 1 |
| Hundt, AF | 1 |
| Salah Fayed, A | 1 |
| Abdel-Aaty Shehata, M | 1 |
| Yehia Hassan, N | 1 |
| El-Weshahy, SA | 1 |
| Gupta, VK | 1 |
| Singh, AK | 1 |
| Gupta, B | 1 |
| Hansen, BJ | 1 |
| Flyger, H | 1 |
| Brasso, K | 1 |
| Schou, J | 1 |
| Nordling, J | 1 |
| Thorup Andersen, J | 1 |
| Mortensen, S | 1 |
| Meyhoff, HH | 1 |
| Walter, S | 1 |
| Hald, T | 1 |
| Lukacs, B | 1 |
| Comet, D | 1 |
| Grange, JC | 1 |
| Thibault, P | 1 |
1 trial available for alfuzosin and Sensitivity and Specificity
| Article | Year |
|---|---|
Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prostatic H | 1995 |
6 other studies available for alfuzosin and Sensitivity and Specificity
| Article | Year |
|---|---|
Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective alpha1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma.
Topics: Adrenergic alpha-Antagonists; Chromatography, Liquid; Drug Stability; Humans; Male; Methyl Ethers; M | 2008 |
Quantitation of alfuzosin hydrochloride in pharmaceutical formulations by RP-HPLC.
Topics: Adrenergic alpha-Antagonists; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Quina | 2009 |
Selective, sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of alfuzosin in human plasma.
Topics: Adrenergic alpha-Antagonists; Chromatography, Liquid; Humans; Quinazolines; Reference Standards; Rep | 2003 |
Validated HPLC and HPTLC stability-indicating methods for determination of alfuzosin hydrochloride in bulk powder and pharmaceutical formulations.
Topics: Adrenergic alpha-Antagonists; Calibration; Chromatography, High Pressure Liquid; Chromatography, Thi | 2006 |
Potentiometric sensors enabling fast screening of the benign prostatic hyperplasia drug alfuzosin in pharmaceuticals, urine and serum.
Topics: Drug Evaluation, Preclinical; Electrochemistry; Electrodes; Humans; Hydrogen-Ion Concentration; Male | 2007 |
Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Anxiety; Case-Control Studies; Cohort | 1997 |